Castle Biosciences, Inc. · NASDAQ:CSTL

Castle Biosciences — FY2024 Earnings Presentation

7 slides from Castle Biosciences's earnings presentation, January 2025

  1. Slide 1: Empowering people, informing care decisions

    Empowering people, informing care decisions Preliminary Fourth Quarter and Year-End Results 2024 January 2025 ©2025 Castle Biosciences 1

  2. Slide 2: Disclaimers

    Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sectio

  3. Slide 3: Registered Trademarks; Preliminary Results

    Registered Trademarks DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, DiffDx- Melanoma, TissueCypher, IDgenetix, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc. Preliminary Results Castle Biosciences has not c

  4. Slide 4: Preliminary Fourth Quarter and Year-end 2024 Performance Results (unaudited)

    Preliminary Fourth Quarter and Year-end 2024 Performance Results1,2 (unaudited) 4Q24 4Q23 2024 2023 Expected to meet Revenue To be $66.1 million or exceed top end $219.8 million announced of guided range of $320-330 million3 Total test reports 24,071 20,284 96,071 70,429 DecisionDx-Melanoma 8,672 8,

  5. Slide 5: 2024 Year-end cash, cash equivalents & marketable investment securities expected to be approximately $293 million

    2024 Year-end cash, cash equivalents & marketable investment securities expected to be approximately $293 million Cash, cash equivalents & marketable investment securities As of 12/31/24 As of 3/31/24 As of 6/30/24 As of 9/30/24 ~$293 million $239.2 million $259.7 million $279.8 million (expected) ©

  6. Slide 6: A disciplined approach to capital allocation

    A disciplined approach to capital allocation Commercial optimization Focused R&D efforts to build evidentiary support and develop tests As a lesser priority, strategic opportunities, including within our current therapeutic areas ©2025 Castle Biosciences 6

  7. Slide 7: Thank You

    Thank You ©2025 Castle Biosciences 7

Castle Biosciences — FY2024 Earnings Presentation on 6ix